

---

**Correction to  
*Lancet Oncol* 2019;  
20: 239–53**

Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. *Lancet Oncol* 2019; **20**: 239–53—In figure 4B of this Article, the position of the plotted Kaplan-Meier curves on the y axis has been corrected, affecting the overall survival readings. This correction has been made to the online version as of March 1, 2019

**Correction to  
*Lancet Oncol* 2019;  
20: 361–70**

Saad ED, Squifflet P, Burzykowski T, et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. *Lancet Oncology* 2019; **20**: 361–70—In the summary of this Article, the fourth sentence of the findings section should read “Subgroups defined by nodal status and hormone receptor status yielded qualitatively similar results.” This correction has been made to the online version as of March 1, 2019, and the printed Article is correct.